BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response

Reuters

Nov 21

BRIEF-Pasithea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 1 Data Including Partial Response

Nov 20 (Reuters) - Pasithea Therapeutics Corp KTTA.O:

PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDING PARTIAL RESPONSE, DEMONSTRATING MONOTHERAPY CLINICAL ACTIVITY AND FAVORABLE SAFETY PROFILE FOR PAS-004 IN ADVANCED CANCER STUDY
PASITHEA THERAPEUTICS CORP: PAS-004 HAS BEEN WELL-TOLERATED WITH ALL TREATMENT-RELATED ADVERSE EVENTS GRADE 1 OR 2

Source text: ID:nGNX9T4V3D

Further company coverage: KTTA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2585168321"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585168321\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585168321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585168321","market":"fut","top_or_hot":-1,"title":"BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pasithea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1 Data Including Partial Response</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Pasithea Therapeutics Corp <span>KTTA.O</span>:</p><ul><li><p>PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDING PARTIAL RESPONSE, DEMONSTRATING MONOTHERAPY CLINICAL ACTIVITY AND FAVORABLE SAFETY PROFILE FOR PAS-004 IN ADVANCED CANCER STUDY</p></li><li><p>PASITHEA THERAPEUTICS CORP: PAS-004 HAS BEEN WELL-TOLERATED WITH ALL TREATMENT-RELATED ADVERSE EVENTS GRADE 1 OR 2</p></li></ul><p>Source text: <span>ID:nGNX9T4V3D</span></p><p>Further company coverage: <span>KTTA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pasithea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1 Data Including Partial Response</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Pasithea Therapeutics Corp <span>KTTA.O</span>:</p><ul><li><p>PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDING PARTIAL RESPONSE, DEMONSTRATING MONOTHERAPY CLINICAL ACTIVITY AND FAVORABLE SAFETY PROFILE FOR PAS-004 IN ADVANCED CANCER STUDY</p></li><li><p>PASITHEA THERAPEUTICS CORP: PAS-004 HAS BEEN WELL-TOLERATED WITH ALL TREATMENT-RELATED ADVERSE EVENTS GRADE 1 OR 2</p></li></ul><p>Source text: <span>ID:nGNX9T4V3D</span></p><p>Further company coverage: <span>KTTA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1JP:1","article_id":"2585168321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585168321","pubTimestamp":1763674739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial ResponseNov 20 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KTTA":"Pasithea Therapeutics Corp."},"translate_title":"简介-Pasithea Therapeutics公布积极的1期数据，包括部分缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KTTA":0.9},"content_text":"BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial ResponseNov 20 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDING PARTIAL RESPONSE, DEMONSTRATING MONOTHERAPY CLINICAL ACTIVITY AND FAVORABLE SAFETY PROFILE FOR PAS-004 IN ADVANCED CANCER STUDYPASITHEA THERAPEUTICS CORP: PAS-004 HAS BEEN WELL-TOLERATED WITH ALL TREATMENT-RELATED ADVERSE EVENTS GRADE 1 OR 2Source text: ID:nGNX9T4V3DFurther company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}